BPC-157 Peptide

## What it is BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide whose sequence is derived from a stable fragment of a larger gastric juice protein characterized in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. Despite the suggestive name, BPC-157 itself is not a naturally occurring molecule; it is a synthetic pentadecapeptide modeled on a region of the parent protein that retained activity in cytoprotection assays. Sikiric's group has authored or co-authored the majority of the published literature, which complicates external replication assessment. The compound has no approved therapeutic indication anywhere in the world. It is not FDA-approved, EMA-approved, or PMDA-approved. The FDA has explicitly stated that BPC-157 does not meet the definition of a dietary supplement and has issued warning letters to compounding pharmacies marketing it. WADA added BPC-157 to its prohibited list in 2022 under the S0 category of non-approved substances, which means competitive athletes face sanctions for any detected use. The entire human use case is experimental and conducted outside regulated medical practice. Distribution is via research-chemical vendors who label product 'for research use only, not for human consumption' as a regulatory shield, and the user base treats that label as a fiction. Quality control across vendors is variable; mass spectrometry studies of grey-market product have found purity ranging from below 50% to above 95%, with no reliable correlation to brand or price. ## Mechanism of action The proposed mechanism is multifactorial and not fully resolved. The most cited pathway is upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) expression and downstream nitric oxide signaling, which would plausibly accelerate angiogenesis at injury sites. Preclinical work has also reported effects on growth hormone receptor expression, modulation of dopamine and serotonin systems in the gut-brain axis, and stabilization of nitric oxide synthase activity in injured tissue. Plasma half-life in rat models is short, on the order of 30 minutes after IV administration. Despite this, sustained tissue effects are observed for hours to days after dosing, suggesting either local tissue accumulation, downstream signaling cascades that outlast the parent peptide, or both. The discrepancy between plasma kinetics and observed effects is one of the structural reasons human pharmacokinetic translation is uncertain. Oral bioavailability in rats appears non-trivial relative to other peptides, which has been used to justify oral dosing protocols, though the supporting human PK data does not exist. The limitation worth stating directly: most of the mechanistic claims rest on a relatively small number of preclinical groups, and the canonical pathways are inferred from receptor and gene expression assays in rodents rather than directly demonstrated in humans. The mechanism is plausible. It is not established. ## Evidence base by outcome The critical context for everything below: there are no completed phase II or phase III human RCTs on BPC-157 as of 2026. The preclinical literature is sizable but the translational gap to humans is unbridged. ### Tendon and ligament healing Roughly 15 rodent studies have reported accelerated healing in surgical Achilles transection, medial collateral ligament injury, and rotator cuff models. Krivic 2008 reported faster Achilles tendon-to-bone reattachment in rats receiving BPC-157 compared to controls. Cerovecki 2010 reported similar effects in MCL injury. Effect sizes are reported as substantial but the studies are small (n of 10 to 20 animals per arm) and the methodology varies. Human translation rests entirely on case reports and self-reported anecdote. ### Gut barrier and mucosal protection Rodent models of NSAID-induced gastric ulceration, ethanol-induced damage, and DSS colitis consistently show faster mucosal recovery in BPC-157-treated animals. The mechanistic story (VEGF-mediated angiogenesis at the gut wall) is internally consistent. Translation to inflammatory bowel disease in humans rests on no controlled data. Anecdotal user reports of symptomatic improvement in IBS and IBD are abundant in online communities and absent from the peer-reviewed literature. ### Joint pain and athletic injury This is the most common use case in the biohacker community and has the weakest evidence. There are no controlled human trials. Case reports and online survey data exist but suffer from selection bias, placebo effects, and the natural history of soft-tissue injury (most resolve in 6 to 12 weeks regardless of intervention). The popular framing of BPC-157 as a tendon-healing peptide is plausible from preclinical signals and unsupported by human data. ### Long-term safety No long-term human safety data exists. Rodent studies out to several months have not flagged organ toxicity at typical experimental doses, but the relevant question for human users (chronic dosing over years at unknown purity) cannot be answered from existing literature. Theoretical concerns include angiogenic effects in active malignancy (VEGF upregulation could plausibly accelerate tumor vascularization) and immunogenicity from injected peptide impurities. ### Bone and other tissue healing Four rodent fracture-healing studies have reported faster callus formation and improved bone remodeling. Six rodent CNS injury studies report neuroprotective signals in models of traumatic brain injury, stroke, and chemical CNS damage. The neuroprotective signals are mechanistically interesting (the gut-brain axis hypothesis is consistent with reported behavioral changes in injured rodents) and clinically untranslated. Treat as preclinical curiosity rather than clinical evidence. ### Replication and publication concerns A structural caveat applies to the entire BPC-157 literature: a substantial fraction of the preclinical work originates from the Sikiric group at the University of Zagreb. Independent replication exists but is sparse relative to the publication volume. The compound has not received significant attention from independent industrial pharmacology programs, which is a reasonable indicator that the case for clinical development was not compelling enough to overcome the regulatory and IP barriers. This pattern is not proof of inefficacy, but it is a relevant base rate when interpreting the literature. ## Dosage and protocols Anecdotal protocols circulating in user communities run 250 to 500 mcg twice daily subcutaneously, ideally near the injury site, for 4 to 6 weeks. A typical 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL, and a 250 mcg dose is 10 units on a U100 insulin syringe. None of these specifics are derived from human dose-finding trials. They are extrapolated from rodent dosing and refined by community feedback. Oral protocols at 500 mcg once or twice daily are also circulating, with the rationale that the parent compound is gastric in origin. Oral bioavailability in humans is unknown. No cycling consensus exists. The most common framing is 4 to 6 weeks on, 4 to 8 weeks off, mirroring the cadence used in rodent injury studies. This cadence is convention rather than evidence. ## Side effects and safety Reported side effects in user surveys are mostly minor: injection-site irritation, transient nausea, occasional headache. No serious adverse events have been documented in published literature, but post-marketing surveillance does not exist for an unregulated compound, and the population using it self-selects for tolerability. Contraindications are theoretical rather than evidence-based. Pregnancy is a hard avoid given total absence of data. Active malignancy is a soft avoid given the angiogenic mechanism. Concurrent immunosuppression and recent surgery are precautionary. Athletes subject to WADA testing should not use it under any circumstances; detection methods exist and the S0 listing is unambiguous. The largest practical safety concern is product quality. Independent mass spec studies of grey-market BPC-157 vials have found wildly variable peptide content, and impurities from solid-phase peptide synthesis can be immunogenic. Sterility of the reconstituted product depends entirely on the bacteriostatic water and aseptic technique. ## Stack interactions and timing Users commonly stack BPC-157 with TB-500 in injury-recovery protocols, on the rationale that the two peptides target distinct healing pathways. There is no human data supporting either the rationale or the safety of the combination. There is no characterized drug-drug interaction profile because there are no human pharmacokinetic studies. Timing within the day appears not to matter from preclinical data. Most user protocols run morning and evening to spread the short plasma half-life across the day, but this is convention rather than measured optimization. ## Practical notes The research-use-only positioning is not a stylistic choice. The compound is unapproved, the safety database is preclinical, and the human evidence is anecdotal. The honest framing is that BPC-157 is interesting preclinical chemistry that has not earned a clinical recommendation and is being used by people who have decided the asymmetric bet works for them. The dose-response, the long-term safety profile, and the indication are all open questions. Reconstituted vials should be refrigerated and used within 30 days. Lyophilized powder is stable at room temperature for the labeled shelf life and should be refrigerated for longer storage. Bacteriostatic water (not sterile water) is the standard reconstitution medium because the benzyl alcohol preservative provides modest protection against bacterial contamination over the 30-day use period. If you are using BPC-157 anyway, accept the framing: this is experimentation, not medicine. Document baseline injury severity, document the protocol, log subjective response, and discontinue if anything unexpected appears. The honest expected value is unknown. Marketing claims of guaranteed healing should be treated as marketing.